Mer­ck­'s PD-1 star Keytru­da flunks a key sur­vival end­point in SCLC — cue the un­fa­vor­able Tecen­triq com­par­isons

Mer­ck’s star check­point drug Keytru­da missed a key end­point in their Phase III tri­al as a front­line ther­a­py for ex­ten­sive-stage small cell lung can­cer, fail­ing to pro­vide a sig­nif­i­cant im­prove­ment in over­all sur­vival.

The drug com­bined with chemo did hit the end­point for sig­nif­i­cance in pro­gres­sion-free sur­vival, leav­ing it in a weak but com­pet­i­tive po­si­tion in this hard-to-treat form of can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER